Gene Modified Immune Cells After Conditioning Regimen for the Treatment of Stage IIIC or IV Melanoma or Metastatic Solid Tumors
Stanford University
Stanford University
Emory University
Endeavor Biomedicines, Inc.
Replimune Inc.
M.D. Anderson Cancer Center
Linnaeus Therapeutics, Inc.
Novelty Nobility, Inc.
Turnstone Biologics, Corp.
Memorial Sloan Kettering Cancer Center
National Cancer Institute (NCI)
The Methodist Hospital Research Institute
University of Florida
Provectus Pharmaceuticals
Opna Bio LLC
Pfizer
Incyte Corporation
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Yale University
Memorial Sloan Kettering Cancer Center
National Institutes of Health Clinical Center (CC)